PF-Atlas › Clinical Trials › NCT01371305
STX-100 in Patients With Idiopathic Pulmonary Fibrosis
BG00011 · Phase 2
Registry ID
NCT01371305
Phase
Phase 2
Status
Completed
Drug / intervention
BG00011
Sponsor
Biogen
Start
2012-07-16
Enrollment
41
Locations
10
About this trial
The primary objective of this study is to evaluate the safety and tolerability of subcutaneously (SC) administered multiple, escalating doses of BG00011 (a humanized monoclonal antibody directed against the alpha v beta 6 (αvβ6) integrin, formerly known as STX-100) in participants with IPF. The Secondary objectives are to estimate the pharmacokinetic (PK) parameters after the 1st dose and after the last dose of multiple, escalating doses of BG00011 in participants with IPF, to assess the immunogenicity of BG00011 in participants with IPF, and to assess the effect of BG00011 on biomarkers isolated from bronchoalveolar lavage (BAL) and peripheral blood in participants with IPF.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT01371305 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.